Diundecyl Phosphatidyl Choline

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: Diundecyl Phosphatidyl Choline
• 英文别名: 2-[[(2R)-2,3-di(dodecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C32H65NO8P+
• 分子量: 622.8
• InChiKey: IJFVSSZAOYLHEE-SSEXGKCCSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  9.2
• 重原子数：
  42
• 可旋转键数：
  32
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Liposomal statin formulation
  申请人：Southwest Research Institute

  公开号：US10716758B2

  公开（公告）日：2020-07-21

  A method of preparing liposomal statins includes preparing a lipid solution including phosphatidylcholine, cholesterol, vitamin-E and an organic solvent and removing the solvent, forming a lipid cake. The lipid cake may then be hydrated with a first aqueous media. The hydrated cake may be mixed in a mixer and subjected to one or more freeze/thaw cycles and then extruded to form liposomes. A cryo-protective agent may be added to the liposomes and the liposomes may be lyophilized to provide a powder. A statin is added to the organic lipid solution or to the first aqueous media used for hydrating the lipid cake.

  一种制备脂质体他汀类药物的方法包括制备包括磷脂酰胆碱、胆固醇、维生素-E 和有机溶剂的脂质溶液，然后除去溶剂，形成脂饼。然后用第一种水介质将脂质饼水合。水合后的脂饼可在混合器中混合，并进行一次或多次冷冻/解冻循环，然后挤出形成脂质体。脂质体中可加入低温保护剂，然后将脂质体冻干，制成粉末。在有机脂溶液或用于水合脂饼的第一种水介质中加入他汀类药物。
• AGENT DELIVERY SYSTEM
  申请人：WRS Nutraceuticals Pty Ltd

  公开号：EP3452052A1

  公开（公告）日：2019-03-13
• COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DIABETES
  申请人：The Broad Institute, Inc.

  公开号：EP3474849A1

  公开（公告）日：2019-05-01
• LIPOSOMAL FORMULATIONS OF AMIDINE SUBSTITUTED BETA-LACTAM COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：AiCuris Anti-infective Cures GmbH

  公开号：EP3541382A1

  公开（公告）日：2019-09-25
• Particulate-stabilized injectable pharmacutical compositions of posaconazole
  申请人：Witchey-Lakshmanan Leonore

  公开号：US20090226527A1

  公开（公告）日：2009-09-10

  The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient Posaconazole in an injectable suspension of particles that is stable when subjected to terminal sterilization. Preferred median particle sizes of between 1.5 and 3.0 microns are found to result in superior pharmacokinetic characteristics-displayed in FIG. 7.